Filing Flows › Lyell Immunopharma (LYEL) › Q2 2026 › vs Q1 2026
Lyell Immunopharma (LYEL) Q2 2026 vs Q1 2026 (quarter over quarter)
Lyell Immunopharma's revenue rose $2K (+100%) from $2K in Q1 2026 to $4K in Q2 2026.
Lyell Immunopharma, Q2 2026: revenue $4K (-50% year over year), net loss $44.8M, operating cash flow −$33.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $4K | $2K | $2K | +100% |
| Other income, net | $2.6M | $20.1M | −$17.5M | -87% |
| Net loss | $44.8M | $24.2M | $20.6M | +85% |
| Costs & expenses | $47.3M | $44.3M | $3.1M | +7% |
| Operating costs | $47.3M | $44.3M | $3.1M | +7% |
| Operating cash sources | $44.8M | $24.2M | $20.6M | +85% |
| Depreciation & amortization | $2.2M | $2.3M | −$110K | -5% |
| Share-based compensation | $4.5M | $4.3M | $237K | +6% |
| Working capital & other | $4.1M | −$21.0M | $25.1M | — |
| Cash used in operations | $33.9M | $38.5M | −$4.6M | -12% |
| Net loss absorbed | $44.8M | $24.2M | $20.6M | +85% |
Questions
How much did Lyell Immunopharma's revenue grow quarter over quarter in Q2 2026?
Lyell Immunopharma's revenue rose $2K (+100%) from $2K in Q1 2026 to $4K in Q2 2026.